Synapse - Michael Mauro

Search Within

Michael John Mauro

Results (273)

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Guidelines

Apperley, J. F.; Milojkovic, D.; Cross, N. C. P.; Hjorth-Hansen, H.; Hochhaus, A.; Kantarjian, H.; Lipton, J. H.; Malhotra, H.; Niederwieser, D.; Radich, J.; more...
Leukemia (2025)

Fulltext@MSK | Save

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results

Journal Article

Cortes, J. E.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
Leukemia (2025)

Fulltext@MSK | Save

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA

Journal Article

Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
Leukemia (2025)

Fulltext@MSK | Save

Pharmacokinetic profile of novel reduced-dose Danziten(TM) (nilotinib tablets) versus Tasigna® (nilotinib capsules): In vivo bioequivalence and population pharmacokinetic analysis

Journal Article

Mauro, M.; Radich, J.; Jain, P.; Sequeira, D.; Bellanti, F.; Douer, D.
Cancer Chemotherapy and Pharmacology (2025)

Fulltext@MSK | Save

First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Meeting Abstract

Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
Blood (2024)

Fulltext@MSK | Save

Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
Blood (2024)

Fulltext@MSK | Save

Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia

Meeting Abstract

Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
Blood (2024)

Fulltext@MSK | Save

Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission in chronic myeloid leukaemia

Meeting Abstract

Kok, C. H.; Saunders, V. A.; Shanmuganathan, N.; Liu, L.; Irani, Y. D.; Clarson, J.; Dang, P.; Yeung, D. T.; Yong, A. S. M.; Branford, S.; more...
Blood (2024)

Fulltext@MSK | Save

Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; more...
Blood (2024)

Fulltext@MSK | Save

Novel nilotinib tablet formulation: Pharmacokinetic characterization and effects of food

Meeting Abstract

Mauro, M. J.; Radich, J. P.; Jain, P.; Sequeira, D.; Douer, D.
Blood (2024)

Fulltext@MSK | Save